Newest Content

Filter
You Filtered On: 2285spk
Keyword Image
Madrigal: Best in Class in NASH?
10/13/2017 5:00 am EST

We recently held a conference call with the management team at Madrigal (MDGL) and came away even mo...

John McCamant Image
John McCamant
Tickers: MDGL
Keyword Image
John McCamant on Anti-Cancer Therapies
09/22/2017 12:17 pm EST

At MoneyShow San Francisco, John McCamant outlines several anti-cancer drug makers and possible bre...

McCamant, John Image
McCamant, John
Duration: 3:29
Keyword Image
Nektar: "A Slew of Good News"
08/10/2017 2:54 am EST

Nektar Therapeutics (NKTR) reported positive top-line Human Abuse Liability (HAL) data for NKTR-181,...

John McCamant Image
John McCamant
Tickers: NKTR
Keyword Image
Intrexon: Mosquitoes & Biotech
07/24/2017 2:50 am EST

Oxitec Ltd., a wholly-owned subsidiary of Intrexon (XON), announced that Oxitec do Brasil has signed...

John McCamant Image
John McCamant
Tickers: XON
Keyword Image
Pacira Targets Opiod Addiction
05/17/2017 2:50 am EST

It's "steady of she goes" at Pacira Pharmaceuticals (PCRX); overall the firm reported a steady quart...

John McCamant Image
John McCamant
Tickers: PCRX
Keyword Image
Incyte: Bad News Buy?
04/26/2017 2:50 am EST

Incyte (INCY) and their partner Eli Lilly (LLY) have received a Complete Response Letter (CRL) from ...

John McCamant Image
John McCamant
Tickers: INCY
Keyword Image
Incyte: Best in Class?
02/23/2017 9:00 am EST

Incyte (INCY) and their partner Lilly announced that the European Commission has granted marketing a...

John McCamant Image
John McCamant
Tickers: INCY